Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …

Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …

Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Introduction Atrial fibrillation (AF), one of the major risk factors for stroke, imposing a
substantial burden to the Swedish health care system. Apixaban has demonstrated …